Evidence map›Paper›PMID 22389706›Full record

ArticlePloS one2012

Absence of RIP140 reveals a pathway regulating glut4-dependent glucose uptake in oxidative skeletal muscle through UCP1-mediated activation of AMPK.

Asmaà Fritah, Jennifer H Steel, Nadeene Parker, Evanthia Nikolopoulou, Mark Christian, David Carling, Malcolm G Parker

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Asmaà FritahInstitute of Reproductive and Developmental Biology, Imperial College, London, United Kingdom. asmaa.fritah@ens-lyon.fr
Jennifer H Steel
Nadeene Parker
Evanthia Nikolopoulou
Mark Christian
David Carling
Malcolm G Parker
Imperial College London · GBUniversity College London · GB

Funding

Medical Research Council MC_U120027537Wellcome TrustWellcome Trust 079200/Z/06/Z
6 · The paper itself

Abstract

Skeletal muscle constitutes the major site of glucose uptake leading to increased removal of glucose from the circulation in response to insulin. Type 2 diabetes and obesity are often associated with insulin resistance that can be counteracted by exercise or the use of drugs increasing the relative proportion of oxidative fibers. RIP140 is a transcriptional coregulator with a central role in metabolic tissues and we tested the effect of modulating its level of expression on muscle glucose and lipid metabolism in two mice models. Here, we show that although RIP140 protein is expressed at the same level in both oxidative and glycolytic muscles, it inhibits both fatty acid and glucose utilization in a fiber-type dependent manner. In RIP140-null mice, fatty acid utilization increases in the extensor digitorum longus and this is associated with elevated expression of genes implicated in fatty acid binding and transport. In the RIP140-null soleus, depletion of RIP140 leads to increased GLUT4 trafficking and glucose uptake with no change in Akt activity. AMPK phosphorylation/activity is inhibited in the soleus of RIP140 transgenic mice and increased in RIP140-null soleus. This is associated with increased UCP1 expression and mitochondrial uncoupling revealing the existence of a signaling pathway controlling insulin-independent glucose uptake in the soleus of RIP140-null mice. In conclusion, our findings reinforce the participation of RIP140 in the maintenance of energy homeostasis by acting as an inhibitor of energy production and particularly point to RIP140 as a promising therapeutic target in the treatment of insulin resistance.

Indexed as

Adaptor Proteins, Signal TransducingAMP-Activated Protein KinasesAnimalsBlotting, WesternGlucoseGlucose Transporter Type 4HumansImmunohistochemistryIon ChannelsMitochondrial ProteinsMuscle, SkeletalNuclear ProteinsNuclear Receptor Interacting Protein 1Signal TransductionUncoupling Protein 1Adaptor Proteins, Signal TransducingAMP-Activated Protein KinasesGlucoseGlucose Transporter Type 4Ion ChannelsMitochondrial ProteinsNRIP1 protein, humanNuclear ProteinsNuclear Receptor Interacting Protein 1UCP1 protein, humanUcp1 protein, mouseUncoupling Protein 1

Identifiers

PMID22389706
PMCPMC3289711
OpenAlexW2112322163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.